<![CDATA[NICE Recommends T-DXd for HER2-Low Metastatic Breast Cancer]]>

Regulatoryapprovedtrastuzumab deruxtecanPositive

AI Analysis

Summary

NICE recommended trastuzumab deruxtecan (T-DXd) for reimbursement in England for HER2-low metastatic breast cancer, supported by DESTINY-Breast04 clinical data.

Clinical Trial Data

Outcome Details

NICE recommended trastuzumab deruxtecan for reimbursement in England for HER2-low metastatic breast cancer

Importance:7/10

Sentiment:

0.85

HER2-low breast cancerNICE recommendationreimbursementDESTINY-Breast04oncology

Related Companies

$DSKYF

Read the original article

Published by Cancer Network on September 18, 2026 1:00 PM

Read Original